PROBIT IV

September 2012-July 2015

At approximately 16 years of age, researchers collected data on growth, adiposity, blood pressure, neurocognitive function, vision, eczema, and lung function. A total of 13,557 adolescents, representing 82% of the original participants, took part in the follow-up.

Intention-to-treat analyses showed that the intervention was associated with a reduced risk of flexural dermatitis at age 16. Researchers found no detectable effect on lung function, asthma, or rates of low vision. Adolescents in the intervention group scored slightly higher on measures of verbal function and memory than those in the control group. Contrary to hypothesis, risk for obesity was slightly higher among participants in the intervention group than in the control group. 

  • 2012-2015:
    Emily Oken, MD, MPH: Harvard Pilgrim Health Care Institute, United States of America
    Michael Kramer, MD: McGill University, Quebec, Canada
    Richard M. Martin, B.Med.Sci., B.M., B.S., M.Sc., M.R.C.G.P., PhD: University of Bristol, United Kingdom

  • 2012-2015: 
    Belarus: Konstantin Vichuck, MD; Natalia Bogdanovich, MD, Mikhail Hameza, BA
    Canada: Seungmi Yang, PhD
    United Kingdom: Carsten Flohr, MD, PhD; John Henderson, MD; Chris Owen, PhD